Evidence map›Paper›PMID 23350987›Full record

ArticleThe FEBS journal2013

Decorin induces rapid secretion of thrombospondin-1 in basal breast carcinoma cells via inhibition of Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase 1.

Thomas Neill, Holly R Jones, Zoe Crane-Smith, Rick T Owens, Liliana Schaefer, Renato V Iozzo

Open access · bronzeAbstract read
In one paragraph

Article in The FEBS journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Decorin: matrix-based pan-cancer tumor suppressor.Molecular and cellular biochemistry · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy.Matrix biology : journal of the International Society for Matrix Biology · 2021
    Article
  10. Review
  11. Review
  12. Review
  13. Proteoglycan-driven Autophagy: A Nutrient-independent Mechanism to Control Intracellular Catabolism.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2020
    Review
  14. hnRNPA2B1 inhibits the exosomal export of miR-503 in endothelial cells.Cellular and molecular life sciences : CMLS · 2020
    Article
  15. Catabolic degradation of endothelial VEGFA via autophagy.The Journal of biological chemistry · 2020
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Thomas NeillDepartment of Pathology, Anatomy, and Cell Biology, and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Holly R Jones
Zoe Crane-Smith
Rick T Owens
Liliana Schaefer
Renato V Iozzo
Sidney Kimmel Cancer Center · USThomas Jefferson University · USGoethe University Frankfurt · DE

Funding

Alcohol Tissue InjuryT32AA007463 · NIAAA · THOMAS JEFFERSON UNIVERSITY · PI HOEK, JOANNES B, VADIGEPALLI, RAJANIKANTH · 1985 to 2021
$9.1M
NEOPLASTIC MODULATION OF PROTEOGLYCAN METABOLISMR01CA039481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI IOZZO, RENATO V. · 1985 to 2020
$7.1M
The Biology of Perlecan in Cancer and AngiogenesisR01CA047282 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 1990 to 2019
$5.7M
Natural EGFR Antagonists and CancerR01CA120975 · NCI · THOMAS JEFFERSON UNIVERSITY · PI IOZZO, RENATO V. · 2007 to 2010
$942k
NCI NIH HHS R01 CA039481NCI NIH HHS R01 CA047282NCI NIH HHS R01 CA120975NCI NIH HHS R01 CA39481NCI NIH HHS R01 CA47282NIAAA NIH HHS T32 AA007463NIAAA NIH HHS T32 AA07463
6 · The paper itself

Abstract

Pathological neovascularization relies on an imbalance between potent proangiogenic agents and equally effective antiangiogenic cues. Collectively, these factors contribute to an angiogenic niche within the tumor microenvironment. Oncogenic events and hypoxia contribute to augmented levels of angiokines, and thereby activate the so-called angiogenic switch to promote aggressive tumorigenic and metastatic growth. Soluble decorin functions as a paracrine pan-inhibitor of receptor tyrosine kinases, such as Met and epidermal growth factor receptor, and thus is capable of suppressing angiogenesis under normoxia. This leads to noncanonical repression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor A (VEGFA), and concurrent induction of thrombospondin-1. The substantial induction of endogenous tumor cell-derived thrombospondin-1, a potent antiangiogenic effector, led us to the discovery of an unexpected secretory phenotype occurring very rapidly (within 5 min) after decorin treatment of the triple-negative basal breast carcinoma cell line MDA-MB-231. Surprisingly, the effect was not mediated by Met receptor antagonism, as initially hypothesized, but required epidermal growth factor receptor signaling to achieve swift and robust thrombospondin-1 release. Furthermore, this effect was ultimately dependent on the prompt degradation of Ras homolog gene family member A, via the 26S proteasome, leading to direct inactivation of Rho-associated coiled-coil containing protein kinase 1. The latter led to derepression of thrombospondin-1 secretion. Collectively, these data provide a novel mechanistic role for Rho-associated coiled-coil containing protein kinase 1, in addition to providing the first conclusive evidence of decorin exclusively targeting a receptor tyrosine kinase to achieve a specific effect. The overall effects of soluble decorin on the tumor microenvironment would cause an immediately-early as well as a sustained antiangiogenic response in vivo.

Indexed as

AmidesBasal Cell CarcinomaBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell Line, TumorCell Transformation, NeoplasticDecorinEnzyme ActivationErbB ReceptorsExosomesHumansNeovascularization, PathologicProteasome Endopeptidase ComplexProteolysisProto-Oncogene Proteins c-metPyridinesRecombinant Fusion ProteinsAmidesATP dependent 26S proteaseBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsDecorinEGFR protein, humanErbB ReceptorsMET protein, humanProteasome Endopeptidase ComplexProto-Oncogene Proteins c-metPyridinesRecombinant Fusion ProteinsrhoA GTP-Binding ProteinRHOA protein, humanrho-Associated KinasesRNA, Small InterferingROCK1 protein, humanSPZ1 protein, humanY 27632

Identifiers

PMID23350987
PMCPMC3648593
OpenAlexW2044625443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.